MBD3L2 Activators
MBD3L2 can influence the expression of this protein through various mechanisms involving alterations to the chromatin structure and DNA methylation patterns. Compounds such as 5-Azacytidine and RG108 can inhibit DNA methyltransferase, leading to reduced methylation levels in the genome. This demethylation can result in the increased expression of MBD3L2 if the protein's regulatory regions in the DNA were previously methylated, which would otherwise suppress transcription. Similarly, Decitabine functions as a cytidine analog that integrates into DNA and inhibits DNA methyltransferase, which can also result in the upregulation of MBD3L2 expression. Zebularine operates in a comparable fashion, targeting DNA methyltransferase to reduce methylation at the MBD3L2 locus. On the other hand, S-Adenosylmethionine serves as a methyl donor in various biological processes, including the methylation of histones. This methylation can activate gene expression, potentially enhancing the production of MBD3L2 if histone methylation near its promoter region acts as an activating signal.
DNA methylation changes, the acetylation status of histones surrounding the MBD3L2 gene plays a crucial role in its expression. HDAC inhibitors such as Trichostatin A, Sodium butyrate, SAHA (Vorinostat), and Disulfiram can increase histone acetylation, leading to a more open and transcriptionally active chromatin state. This relaxed chromatin structure can facilitate the binding of transcription machinery to the promoter region of MBD3L2, promoting its expression. Resveratrol engages with sirtuins to modulate deacetylation processes, which can affect the transcription of MBD3L2. Parthenolide's mechanism involves the inhibition of NF-κB, a factor known to repress gene expression. By inhibiting NF-κB, Parthenolide can lift the repressive effects on MBD3L2, allowing for its activation. Lastly, Genistein's role as a tyrosine kinase inhibitor can prevent the phosphorylation of proteins that are involved in the repression of MBD3L2, thereby enabling its activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine by inhibiting DNA methyltransferase can cause hypomethylation of DNA, leading to the activation of genes that are otherwise silenced. This may include activation of MBD3L2 if its expression is epigenetically repressed. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). Inhibition of HDACs can result in a more relaxed chromatin structure, potentially facilitating the activation of MBD3L2 by allowing transcriptional machinery access. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, as an HDAC inhibitor, can promote a relaxed chromatin state, which could enable the activation of MBD3L2 by making its promoter region more accessible for transcription factors and coactivators. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA, another HDAC inhibitor, can enhance acetylation of histones, leading to a chromatin state conducive to gene activation. MBD3L2, in this environment, might be more actively transcribed and translated into functional protein. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a non-nucleoside DNA methyltransferase inhibitor, which could prevent methylation of the MBD3L2 promoter, potentially resulting in its activation if it is normally silenced by methylation. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide inhibits NF-κB, a transcription factor that can repress gene expression. Inhibition could relieve repression on MBD3L2, leading to its activation if NF-κB normally suppresses MBD3L2 expression. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor, which might enhance the activation of MBD3L2 by blocking kinases that phosphorylate repressive signaling molecules, thereby preventing repression of MBD3L2. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol can activate sirtuins, which may lead to the deacetylation of specific transcription factors or coactivators, thereby activating the expression of genes like MBD3L2, if they are regulated by these factors. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
Zebularine inhibits DNA methyltransferase, potentially leading to reduced methylation and activation of MBD3L2 if DNA methylation is a regulatory mechanism for its expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine is a cytidine analog that inhibits DNA methyltransferase, potentially resulting in the demethylation and subsequent activation of MBD3L2 if methylation is a key regulatory mechanism. | ||||||